This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.
Original paper

ATIM-14. RESULTS OF PHASE II CLINICAL TRIAL OF ONCOLYTIC HERPES VIRUS G47Δ IN PATIENTS WITH GLIOBLASTOMA

Volume: 21, Issue: Supplement_6, Pages: vi4 - vi4
Published: Nov 1, 2019
Abstract
Genetically engineered, conditionally replicating herpes simplex viruses type 1 (HSV-1) are promising therapeutic agents for cancer. We have developed a triple-mutated, third-generation oncolytic HSV-1, G47∆, that exhibits enhanced replication capability in a variety of cancer, efficient induction of specific antitumor immunity, and high safety features. G47∆ also kills cancer stem cells very efficiently. The first-in-man, phase I-IIa study of...
Paper Details
Title
ATIM-14. RESULTS OF PHASE II CLINICAL TRIAL OF ONCOLYTIC HERPES VIRUS G47Δ IN PATIENTS WITH GLIOBLASTOMA
Published Date
Nov 1, 2019
Volume
21
Issue
Supplement_6
Pages
vi4 - vi4
© 2025 Pluto Labs All rights reserved.
Step 1. Scroll down for details & analytics related to the paper.
Discover a range of citation analytics, paper references, a list of cited papers, and more.